<DOC>
	<DOCNO>NCT00086671</DOCNO>
	<brief_summary>The objective trial study safety effectiveness ABT-874 administer weekly every week patient relapse remit secondary progressive multiple sclerosis compare placebo . Effectiveness measure base MRI scan do periodically throughout study .</brief_summary>
	<brief_title>Safety Effectiveness Two Doses ABT-874 Compared Placebo Subjects With Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>This study do subject relapse remit MS secondary progressive MS objective assess safety efficacy 200 mg ABT-874 weekly QOW versus placebo . There 3 phase study , 24 week double blind follow 24 week active extension , follow 48 week double blind active extension . The trial discontinue Abbott Aug 2006 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 55 year Diagnosis active relapse within 12 month screen . At least one relapse within 12 month screen . Must able walk least 65 foot without assistance Off Copaxone interferon therapy two month prior screen Able willing learn selfadminister weekly injection , designee administer study medication Female participant must use contraceptive study drug Primary progressive multiple sclerosis ( PPMS ) Immunosuppressive therapy ( azathioprine , methotrexate ( MTX ) , exclude corticosteroid ) within six month randomization . Subjects previous treatment cyclophosphamide , total lymphoid irradiation , mitoxantrone , cladribine , bone marrow transplantation , regardless duration , exclude participation study Systemic corticosteroid therapy within four week prior first screen Magnetic Resonance Imaging ( MRI ) Participation clinical study , whether involves investigational drug within three month prior screen visit Use investigational drug diseasemodifying potential treatment multiple sclerosis ( MS ) within six month randomization ( prior use investigational agent symptomatic treatment MS , e.g. , 4aminopyridine ( 4AP ) , may allow follow discussion medical monitor Concomitant statin use dose exceed manufacturer ' maximum recommend daily dosage treatment hypercholesterolemia part MS diseasemodifying protocol Infection risk factor severe infection Excessive immunosuppression factor associate , include human immunodeficiency virus ( HIV ) infection Severe , recurrent , persistent infection [ Hepatitis B C , borreliosis recurrent urinary tract infection ( UTI ) ( &gt; 3 UTIs require antibiotic treatment per year ) recurrent pneumonia ( &gt; 2 pneumonia require antibiotic treatment per year ) infect decubitus ulcer ] Evidence current inactive tuberculosis ( TB ) infection ; recent exposure mycobacterium tuberculosis ( converter positive purify protein derivative [ PPD ] ) . Subjects positive PPD chest Xray suggestive prior TB infection exclude Active tuberculosis disease Active chronic Lyme disease Active syphilis Any significant infection require hospitalization intravenous ( IV ) antibiotic month prior Screening ; Infection require treatment antibiotic two week prior Screening . Any following risk factor development malignancy : History lymphoma leukemia Cutaneous squamouscell basal cell carcinoma ( EXCEPT treat two year prior Screening evidence recurrence residual disease ) Other malignancy ( EXCEPT treat five year prior Screening without evidence recurrence residual disease ) Disease associate increase risk malignancy ( familial polyposis ) . History major immunologic reaction ( serum sickness anaphylactoid reaction ) Immunoglobulin G ( IgG ) contain agent ( intravenous ( IV ) gamma globulin , fusion protein , monoclonal antibody ) Confounders assessment neurologic response include disease produce chronic neurologic manifestation ( amyotrophic lateral sclerosis , GuillainBarre syndrome , Lyme disease , myasthenia gravis , etc . ) Prior exposure antiIL12 antibodies Confounders safety assessment , unstable medical condition relate MS ( include require adjustment treatment four week prior Screening ) Exacerbation asthma require hospitalization ten year prior Screening ( subject asthma require hospitalization discuss medical monitor prior Screening ) Pregnant lactate females The following exclusionary laboratory value screen baseline : Hemoglobin ( Hgb ) &lt; 10 g/dL female &lt; 12 g/dL male ; White blood cell ( WBC ) count &lt; 3 x 109/L ; Platelet count &lt; 100 x 109/L Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) x 3 upper limit normal ( ULN ) ; Serum total bilirubin &gt; /= 3 mg/dL ( &gt; /= 51 x mol/L ) Serum creatinine &gt; 1.6 mg/dL ( &gt; 141 x mol/L ) Subject recent history substance abuse psychiatric illness could preclude compliance protocol In eight week prior study drug administration , subject receive transfusion blood product , 500 mL blood remove repetitive onetime blood donation , plasmapheresis , plasma exchange , lose 550 mL blood hemorrhage ; For reason , subject consider investigator unsuitable candidate receive ABT874 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>